Metformin: From Immediate Release to Extended Release Formula, Effectiveness, And Safety in Patients With Chronic Kidney Disease

G. Derosa, R. Rivera, A. D'Angelo, P. Maffioli
{"title":"Metformin: From Immediate Release to Extended Release Formula, Effectiveness, And Safety in Patients With Chronic Kidney Disease","authors":"G. Derosa, R. Rivera, A. D'Angelo, P. Maffioli","doi":"10.33590/emjdiabet/19-00177","DOIUrl":null,"url":null,"abstract":"Type 2 diabetes mellitus is currently the main cause of chronic kidney disease, leading to end-stage renal disease in most countries around the world. Metformin is the most commonly prescribed oral antihyperglycaemic in the world and after approval by the U.S. Food and Drug Administration (FDA) in 1994, it is currently recommended as the first-line pharmacological agent for newly diagnosed Type 2 diabetes mellitus by many professional diabetes associations. In this review, the authors analysed efficacy and safety of metformin in patients with chronic kidney disease.","PeriodicalId":418035,"journal":{"name":"EMJ Diabetes","volume":"40 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EMJ Diabetes","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33590/emjdiabet/19-00177","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Type 2 diabetes mellitus is currently the main cause of chronic kidney disease, leading to end-stage renal disease in most countries around the world. Metformin is the most commonly prescribed oral antihyperglycaemic in the world and after approval by the U.S. Food and Drug Administration (FDA) in 1994, it is currently recommended as the first-line pharmacological agent for newly diagnosed Type 2 diabetes mellitus by many professional diabetes associations. In this review, the authors analysed efficacy and safety of metformin in patients with chronic kidney disease.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
二甲双胍:从立即释放到缓释配方,在慢性肾病患者中的有效性和安全性
2型糖尿病是目前慢性肾脏疾病的主要原因,在世界上大多数国家导致终末期肾脏疾病。二甲双胍是世界上最常用的口服降糖药,1994年获得美国食品药品监督管理局(FDA)批准后,目前被许多专业糖尿病协会推荐为治疗新诊断的2型糖尿病的一线药物。在这篇综述中,作者分析了二甲双胍在慢性肾病患者中的疗效和安全性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Review of the 59th European Association for the Study of Diabetes (EASD) Annual Meeting Preconception Care for Individuals with Diabetes EASD 2023 Abstract Highlights Hidden Complication of Obesity and Diabetes: Is It Time to Put More Focus on Fatty Liver? Mean Platelet Volume in Type 2 Diabetes: Correlation with Poor Glycaemic Control
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1